A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-09-23
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 13); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 31); relationship: N
severe
assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-10 (study day 91); relationship: not assessed
Data queries
No data queries.